ImmunoGen, Inc.

About ImmunoGen, Inc.

Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters.

ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC. Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Website	http://www.immunogen.com
Employees	201-500 employees View all ImmunoGen, Inc. employees
Industry	Biotechnology
Location	830 Winter Street, Waltham, Massachusetts 02451, US
Founded	1981
Keywords	Aml, Adcs, Ovarian Cancer, Ovarian Cancer, Adcs, Antibody-Drug Conjugates, Antibody-Drug Conjugates, Bpdcn, Heme Malignancies, Aml